The Harms of Antipsychotic Drugs: Evidence from Key Studies

Drug Safety

Volumn 40, Issue 1, 2017, Pages 3-14

  Moore, Thomas J ^a,b   Furberg, Curt D ^c  

^a INSTITUTE FOR SAFE MEDICATION PRACTICES   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AMYGDALA; ARTICLE; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; EARLY INTERVENTION; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY TUBERCLE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SHORT COURSE THERAPY; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ALGORITHM; METHODOLOGY; RECURRENT DISEASE; TREATMENT FAILURE;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTIC DISORDERS; RECURRENCE; RESEARCH DESIGN; SCHIZOPHRENIA; TREATMENT FAILURE;

EID: 84995803035     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-016-0475-0     Document Type: Article

References (42)

1. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification system: structure and principles. WHOCC. 2011. http://www.whocc.no/atc/structure_and_principles/. Accessed 9 Jul 2016.
2. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Education/Medical; 2011.
3. Baldessarini RJ, Cole JO, Davis JM, Gardos G. Task Force Report 18: tardive dyskinesia. Report of the American Psychiatric Association Task Force on late neurological effects of antipsychotic drugs. Washington, DC: American Psychiatric Association; 1980.
4. Lawrence RE, First MB, Lieberman JA. Schitzophrenia and other psychoses. Psychiatry Vol. 2. 4th ed. West Sussex: Wiley-Blackwell; 2015.
5. Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011;17:97–103.
6. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96.
7. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology. 2001;25:633–41.
8. Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology. 2008;33:3111–25.
9. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156:869–75.
10. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155:921–8.
11. Sadock BJ, Sadock VA. Kaplan and Sadock’s synopsis of psychiatry: behavioral sciences/clinical psychiatry. 11th ed. Philadelphia (PA): LWW; 2014.
12. Kapur S, Remington G, Zipursky RB, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 1995;57:PL103–7.
13. Kapur S, Zipursky R, Roy P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology. 1997;131:148–52.
14. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514–20.
15. Beaulieu J-M, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63:182–217.
16. Mosholder AD. Review and evaluation of clinical data NDA 20-639 quetiapine fumarate seroquel. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 1997.
17. Chuen MM, Dubitsky GM. Clinical review NDA 22-047 quetiapine fumarate sustained-released tablets. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2007.
18. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97–9.
19. Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31:2318–25.
20. Simpson GM, Angus JWS. Modified Simpson-Angus Scale. Acta Psychiatr Scand. 1970;212(Suppl. 44):9–11.
21. Gharabawi GM, Bossie CA, Lasser RA, et al. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res. 2005;77:119–28.
22. Tarsy D, Parihar R. Tardive syndromes: clinical manifestations, pathophysiology, and epidemiology. Cambridge: Cambridge University Press; 2015. p. 195.
23. Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo: the Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42:233–46.
24. Hoberman D. Statistical review and evaluation: NDA 20-639 seroquel (quetiapine). Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 1997.
25. ®. Brexpiprazole tablet prescribing information [package insert]. Tokyo: Otsuka America Pharmaceutical, Inc.; 2015.
26. Farchione T. Clinical review Brexpiprazole (Rexulti) NDA 205422. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2015.
27. Kordzakhia G. Statistical review and evaluation: brexipiprazole NDA # 205, 422/O-2. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2015.
28. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52:173–88.
29. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6:325–37.
30. Chen Y-F. Statistical review and evaluation Abilitat (aripiprazole) tabs. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2002.
31. Csernansky JG, Mahmoud R. Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16–22.
32. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162:947–53.
33. Jansen LH, Hojyo-Tomoko LH, Kligman LH. Editorial: drugs causing weight gain. BMJ. 1974;1:168.
34. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–97.
35. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.
36. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29:15–31.
37. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193:279–88.
38. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003;290:2693–702.
39. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–87.
40. Bakker PR, de Groot IW, van Os J, van Harten PN. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One. 2011;6:e25588.
41. Jin H, Shih PB, Golshan S, et al. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. J Clin Psychiatry. 2013;74:10–8.
42. Jeste DV, Maglione JE. Atypical antipsychotics for older adults: are they safe and effective as we once thought? J Comp Eff Res. 2013;2:355–8.